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Evaluation of a discharge medication access service
program at two large tertiary medical centers

Eva Huang, PharmD; Theresa Morikawa, PharmD, MBA, BCACP; Adam Saulles, PharmD, BCACP, CSP
Background
•According to the 2017 Truven Health Analytic-NPR
Health Poll, medication cost is the most-cited reason
among respondents for not filling their prescriptions.1
•This cost barrier may exist when patients are
prescribed new medications at discharge from
hospitalization. Insurance coverage and issues are
often unidentified until patients present to the
pharmacy. Ultimately, this may result in delay in
medication initiation, increase stress for patients and
caregivers, and reduce throughput in the hospital and
pharmacy.
•Pharmacy interventions on medication prior
authorizations (PA) have shown to reduce delays in
hospital discharge and significantly improve time to PA
approval, time to first-fill, and time to first-up.2,3
•Beginning end of March 2021, a discharge medication
access service (DMAS) program was piloted in the
integrated pharmacies of two large tertiary medical
centers in the Portland metropolitan areas, Oregon.
•The program features include benefits investigation,
affordability assessment, prior authorization facilitation,
and communication with hospital care team via
progress notes and electronic health record
messaging.
•This proactive approach allows the pharmacy to
provide accurate and consistent cost information to the
patients and hospital providers.
•Program goals include:
•Improving patient experience and continuity of care
•Improving patient safety and reducing readmissions
•Improving pharmacy resource utilization

Discussion
Rx Capture Rate and Prescribing Trend

Rx Capture Rate and Prescribing Trends
• Consistent growth of eligible medication orders and Rx
capture rate by the integrated pharmacies is
demonstrated since DMAS implementation. The number
of eligible prescription orders and discharge prescription
capture rate increased by 86% and 10% from Q1 2021 to
Q1 2022, respectively.
• The medications with the largest difference in capture
rate from pre- to post-DMAS implementation are SGLT2
inhibitors (+9%), lacosamide (+13%), and PCSK9
inhibitors (+26%).
Financial Implications
• There is continuous growth in total pharmacy margins
since DMAS implementation. Of note, the total pharmacy
margin increased by 260% in approximately one year
from Q1 2021 to Q1 2022.
• The growth in prescribing and patient retention were key
contributors to total margin growth. Since DMAS
implementation, patient retention has increased from
7.9% to 11.2% for those who were served by DMAS and
dispensed with one of the studied medications.
• Despite the growth in pharmacy margin, the average
patient out-of-pocket medication cost per eligible
medication dispensed remains similar ($23.87 pre-DMAS
and $24.28 post-DMAS).

Objectives
•The primary objective is to describe DMAS’s impact on
medication prescribing trends and pharmacy
prescription capture rate at hospital discharge.
•Secondary objectives include evaluating DMAS’s
financial impact for the pharmacy and patient as well on
patient retention.

Pharmacy Finance and Patient Retention

Conclusion
• This retrospective review shows promising patient care
and financial outcomes with proactive pharmacy-led
benefits investigation for high-cost medications at
discharge.
Study Limitations
• Retrospective data review
• Inability to assess long-term patient outcomes and
pharmacy utilization due to study time constraints
• Due to limited data availability, the pre- and post-program
implementation time periods for evaluation of prescribing
data were disproportional.
• One potential confounder for the change in prescribing
trend is the emerging literature and change in guideline
recommendations favoring the utilization of SGLT2
inhibitors and ARNI.

Methods
•Study design
•Institutional Review Board-Approved study
•Retrospective review of the following:
•Outpatient medication orders and prescription
records from health system electronic health record
(March 2020 to March 2022)
•Dispensing data from outpatient pharmacy report
(January 2021 to December 2021)

Next Steps
•Longitudinal follow-up studies to investigate the
intervention’s long-term impact on hospital and pharmacy
throughout and patient care outcomes, such as
readmission rate, length of stay, and time to discharge.
•Direct oral anticoagulants and other medications of high
utility and cost may be considered for future program
expansion. Alternatively, the current included medications
may be investigated to optimize DMAS resource
allocation.

•Inclusion criteria
•Hospitalized adult patients at the two studied large
tertiary medical centers (inpatient and outpatientbased patient class)
•Encounter with an active inpatient order for any of the
following medications:
•SGLT2 inhibitors (empagliflozin, dapagliflozin,
canagliflozin, ertugliflozin)
•ARNI (sacubitril-valsartan)
•Platelet aggregation inhibitors (ticagrelor, prasugrel)
•PCSK9 Inhibitors (evolocumab, alirocumab)
•Rifaximin
•Lacosamide
•Exclusion criteria
•Pediatric patients (age <18 years)

DMAS Implementation
• From Quarter 1 (Q1) 2021 to Q1 2022, 1325 new start
medication orders have been serviced by DMAS
program.
• Of the 1025 serviced patients, 24% had a medication
order that required prior authorization and 77% were
provided with a 1-month free medication trial card.
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1. Hobson K. Why do people stop taking their meds? cost is just one reason. NPR.
https://www.npr.org/sections/health-shots/2017/09/08/549414152/why-do-people-stoptaking-their-meds-cost-is-just-one-reason. Published September 8, 2017. Accessed March
13, 2022.
2. Cutler T, She Y, Barca J, et al. Impact of Pharmacy Intervention on Prior Authorization
Success and Efficiency at a University Medical Center. J ManagCare Spec Pharm.
2016;22(10):1167-1171.
3. Lew T, BethishouL, Shieh L. Earlier identification of medications needing prior authorization
can reduce delays in hospital discharge. California Journal of Health System Pharmacists.
2018;30(3):80-85.

